Abstract
349P - Reduced-intensity bevacizumab in progressive glioblastoma multiforme (GBM) is associated with similar overall survival versus standard-dosing
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have